Ignite Creation Date:
2024-05-05 @ 10:23 AM
Last Modification Date:
2024-10-26 @ 9:05 AM
Study NCT ID:
NCT00005950
Status:
TERMINATED
Last Update Posted:
2013-01-23
First Post:
2000-07-05
Brief Title:
506U78 in Treating Patients With Recurrent or Refractory Non-Hodgkins Lymphoma or T-cell Lymphoma
Sponsor:
National Cancer Institute NCI
Organization:
National Cancer Institute NCI
Study Overview
Official Title:
Phase II Study of 506U78 NSC 686673 for Patients With Relapsed or Refractory Indolent B-Cell or Peripheral T-Cell Lymphoma
Status:
TERMINATED
Status Verified Date:
2013-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Administratively complete
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Phase II trial to study the effectiveness of 506U78 in treating patients who have recurrent or refractory non-Hodgkins lymphoma or T-cell lymphoma Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die
Detailed Description:
OBJECTIVES
I Determine the response rate failure-free survival and progression-free survival of patients with recurrent or refractory indolent B-cell non-Hodgkins lymphoma or peripheral T-cell lymphoma when treated with 506U78
II Assess the pharmacokinetics and toxicity of this treatment in these patients
OUTLINE
Patients receive 506U78 IV over 2 hours on days 1 3 and 5 Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity
Patients are followed every 3 months
I Determine the response rate failure-free survival and progression-free survival of patients with recurrent or refractory indolent B-cell non-Hodgkins lymphoma or peripheral T-cell lymphoma when treated with 506U78
II Assess the pharmacokinetics and toxicity of this treatment in these patients
OUTLINE
Patients receive 506U78 IV over 2 hours on days 1 3 and 5 Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity
Patients are followed every 3 months
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| CDR0000067894 | REGISTRY | PDQ Physician Data Query | httpsreporternihgovquickSearchN01CM17003 |
| ID99-208 | None | None | None |
| N01CM17003 | NIH | None | None |